Evidence map›Paper›PMID 28838189›Full record

ArticleThe Journal of infectious diseases2017

Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.

Lisa Menning, Gaurav Garg, Deepa Pokharel, Elizabeth Thrush, Margaret Farrell, Frederic Kunjbe Kodio, Chantal Laroche Veira, Sarah Wanyoike, Suleman Malik, Manish Patel and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. [Cuban experience in immunization, 1962-2016Experiência cubana em imunização, 1962-2016].Revista panamericana de salud publica = Pan American journal of public health · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Lisa MenningWorld Health Organization.
Gaurav GargGavi, the Vaccine Alliance, Geneva, Switzerland.
Deepa PokharelEastern and Southern Africa Regional Office, United Nations Children's Fund (UNICEF), Nairobi, Kenya.
Elizabeth ThrushPan American Health Organization, Washington, D. C.
Margaret FarrellProgramme Division, UNICEF, New York, New York.
Frederic Kunjbe KodioWestern and Central Africa Regional Office, UNICEF, Dakar, Senegal.
Chantal Laroche VeiraTask Force for Global Health, Atlanta, Georgia.
Sarah WanyoikeTask Force for Global Health, Atlanta, Georgia.
Suleman MalikProgramme Division, UNICEF, New York, New York.
Manish PatelTask Force for Global Health, Atlanta, Georgia.
Oliver RosenbauerWorld Health Organization.
The Task Force for Global Health · USUnited Nations Children's Fund · USWorld Health Organization - Pakistan · PKGavi · CHWest and Central African Council for Agricultural Research and Development · SNWorld Health Organization Regional Office for the Americas · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

The requirements under objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018-to introduce at least 1 dose of inactivated poliomyelitis vaccine (IPV); withdraw oral poliomyelitis vaccine (OPV), starting with the type 2 component; and strengthen routine immunization programs-set an ambitious series of targets for countries. Effective implementation of IPV introduction and the switch from trivalent OPV (containing types 1, 2, and 3 poliovirus) to bivalent OPV (containing types 1 and 3 poliovirus) called for intense global communications and coordination on an unprecedented scale from 2014 to 2016, involving global public health technical agencies and donors, vaccine manufacturers, World Health Organization and United Nations Children's Fund regional offices, and national governments. At the outset, the new program requirements were perceived as challenging to communicate, difficult to understand, unrealistic in terms of timelines, and potentially infeasible for logistical implementation. In this context, a number of core areas of work for communications were established: (1) generating awareness and political commitment via global communications and advocacy; (2) informing national decision-making, planning, and implementation; and (3) in-country program communications and capacity building, to ensure acceptance of IPV and continued uptake of OPV. Central to the communications function in driving progress for objective 2 was its ability to generate a meaningful policy dialogue about polio vaccines and routine immunization at multiple levels. This included efforts to facilitate stakeholder engagement and ownership, strengthen coordination at all levels, and ensure an iterative process of feedback and learning. This article provides an overview of the global efforts and challenges in successfully implementing the communications activities to support objective 2. Lessons from the achievements by countries and partners will likely be drawn upon when all OPVs are completely withdrawn after polio eradication, but also may offer a useful model for other global health initiatives.

Indexed as

Disease EradicationImmunization ProgramsCommunity Health PlanningDecision Making, OrganizationalGlobal HealthHumansPoliomyelitisPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralPoliovirus Vaccine, InactivatedPoliovirus Vaccine, Oraladvocacycommunicationsendgameeradicationimmunizationinactivated poliomyelitis vaccineIPVOPVoral poliomyelitis vaccinePoliopoliovirusvaccine

Identifiers

PMID28838189
PMCPMC5853901
OpenAlexW2735628635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.